Literature DB >> 11106551

Deregulation of the Rb and p53 pathways in uveal melanoma.

M A Brantley1, J W Harbour.   

Abstract

Uveal melanoma is the most common primary eye cancer, yet its molecular pathogenesis is poorly understood. In this study, we investigated the immunohistochemical expression of proteins in the Rb and p53 tumor suppressor pathways in 33 uveal melanomas from enucleated eyes. Strong nuclear staining for Rb was present in most tumors. However, a few cases displayed weak nuclear staining and strong cytoplasmic staining (possibly indicating Rb mutation), and this aberrant staining correlated strongly with failed radiotherapy or thermotherapy before enucleation. Staining for cyclin D1 was positive in most tumors and was associated with advanced age and larger tumor size, which are both poor prognostic factors. Generally, immunostaining for p53 was weak (suggesting a lack of p53 mutations), although p53 positivity correlated strongly with staining for phosphorylated Rb, supporting the notion that inappropriate phosphorylation of Rb can induce p53. Strong immunostaining for MDM2, which can functionally block p53 activity, was observed in most tumors and correlated significantly with female sex. Strong cytoplasmic staining was observed for Bcl2, which can inhibit both p53-dependent and -independent apoptosis. We conclude that Rb and p53 are mutated infrequently in uveal melanoma, but their respective pathways may be functionally inactivated.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11106551      PMCID: PMC1885790          DOI: 10.1016/s0002-9440(10)64817-1

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  46 in total

Review 1.  Signaling to p53: breaking the MDM2-p53 circuit.

Authors:  C Prives
Journal:  Cell       Date:  1998-10-02       Impact factor: 41.582

Review 2.  Malignant melanoma: modern black plague and genetic black box.

Authors:  L Chin; G Merlino; R A DePinho
Journal:  Genes Dev       Date:  1998-11-15       Impact factor: 11.361

3.  The prognostic significance of c-myc oncogene expression in uveal melanoma.

Authors:  J S Chana; I A Cree; A J Foss; J L Hungerford; G D Wilson
Journal:  Melanoma Res       Date:  1998-04       Impact factor: 3.599

Review 4.  The retinoblastoma protein pathway in cell cycle control and cancer.

Authors:  J Bartek; J Bartkova; J Lukas
Journal:  Exp Cell Res       Date:  1997-11-25       Impact factor: 3.905

Review 5.  p53, the cellular gatekeeper for growth and division.

Authors:  A J Levine
Journal:  Cell       Date:  1997-02-07       Impact factor: 41.582

6.  Metastatic risk for distinct patterns of postirradiation local recurrence of posterior uveal melanoma.

Authors:  J W Harbour; D H Char; S Kroll; J M Quivey; J Castro
Journal:  Ophthalmology       Date:  1997-11       Impact factor: 12.079

7.  Mdm2 promotes the rapid degradation of p53.

Authors:  Y Haupt; R Maya; A Kazaz; M Oren
Journal:  Nature       Date:  1997-05-15       Impact factor: 49.962

8.  Analysis of p16 (CDKN2/MTS-1/INK4A) alterations in primary sporadic uveal melanoma.

Authors:  S L Merbs; D Sidransky
Journal:  Invest Ophthalmol Vis Sci       Date:  1999-03       Impact factor: 4.799

9.  Expression patterns of cyclin D1 and related proteins regulating G1-S phase transition in uveal melanoma and retinoblastoma.

Authors:  S E Coupland; N Bechrakis; A Schüler; I Anagnostopoulos; M Hummel; N Bornfeld; H Stein
Journal:  Br J Ophthalmol       Date:  1998-08       Impact factor: 4.638

Review 10.  The relationship between BcI2, Bax and p53: consequences for cell cycle progression and cell death.

Authors:  A Basu; S Haldar
Journal:  Mol Hum Reprod       Date:  1998-12       Impact factor: 4.025

View more
  32 in total

Review 1.  Eye cancer: unique insights into oncogenesis: the Cogan Lecture.

Authors:  J William Harbour
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-05       Impact factor: 4.799

Review 2.  The genetics of uveal melanoma: an emerging framework for targeted therapy.

Authors:  J William Harbour
Journal:  Pigment Cell Melanoma Res       Date:  2012-02-13       Impact factor: 4.693

Review 3.  Emerging roles of microRNAs and their implications in uveal melanoma.

Authors:  Chun Yang; Yuejiao Wang; Pierre Hardy
Journal:  Cell Mol Life Sci       Date:  2020-08-11       Impact factor: 9.261

4.  Suppression of thrombospondin-1 expression during uveal melanoma progression and its potential therapeutic utility.

Authors:  Shoujian Wang; Aneesh Neekhra; Daniel M Albert; Christine M Sorenson; Nader Sheibani
Journal:  Arch Ophthalmol       Date:  2012-03

Review 5.  Molecular pathology of uveal melanoma.

Authors:  S E Coupland; S L Lake; M Zeschnigk; B E Damato
Journal:  Eye (Lond)       Date:  2012-12-07       Impact factor: 3.775

6.  Genetics of uveal melanoma and cutaneous melanoma: two of a kind?

Authors:  Thomas van den Bosch; Emine Kilic; Dion Paridaens; Annelies de Klein
Journal:  Dermatol Res Pract       Date:  2010-06-06

Review 7.  Emerging insights into the molecular pathogenesis of uveal melanoma.

Authors:  Solange Landreville; Olga A Agapova; J William Harbour
Journal:  Future Oncol       Date:  2008-10       Impact factor: 3.404

Review 8.  Malignant melanoma in the 21st century: the emerging molecular landscape.

Authors:  Aleksandar Sekulic; Paul Haluska; Arlo J Miller; Josep Genebriera De Lamo; Samuel Ejadi; Jose S Pulido; Diva R Salomao; Erik C Thorland; Richard G Vile; David L Swanson; Barbara A Pockaj; Susan D Laman; Mark R Pittelkow; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2008-07       Impact factor: 7.616

9.  Oncogenic mutations in GNAQ occur early in uveal melanoma.

Authors:  Michael D Onken; Lori A Worley; Meghan D Long; Shenghui Duan; M Laurin Council; Anne M Bowcock; J William Harbour
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-08-21       Impact factor: 4.799

Review 10.  Molecular prognostic testing and individualized patient care in uveal melanoma.

Authors:  J William Harbour
Journal:  Am J Ophthalmol       Date:  2009-10-02       Impact factor: 5.258

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.